Related Experiment Video
Updated: Aug 6, 2025
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Differentiation therapy for murine myelofibrosis model with MLN8237 loaded low-density lipoproteins
Binghong He1, Chao Wang2, Fuping Wang1
1Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University; Beijing 100875, China.
Abstract:
Primary myelofibrosis (PMF) is a severe myeloproliferative neoplasm that is characterized by low-differentiation megakaryoblasts and progressive bone marrow fibrosis. Although an Aurora kinase A (AURKA) targeting small-molecule inhibitor MLN8237 has been approved in clinical trials for differentiation therapy of high-risk PMF patients, its off-target side effects lead to a partial remission and serious complications. Here, we report a dual-targeting therapy agent (rLDL-MLN) with great clinical translation potential for differentiation therapy of PMF disease. In particular, the reconstituted low-density lipoprotein (rLDL) nanocarrier and the loaded MLN8237 can actively target malignant hematopoietic stem/progenitor cells (HSPCs) via LDL receptors and intracellular AURKA, respectively. In contrast to free MLN8237, rLDL-MLN effectively prohibits the proliferation of PMF cell lines and abnormal HSPCs and significantly induces their differentiation, as well as prevents the formation of erythrocyte and megakaryocyte colonies from abnormal HSPCs. Surprisingly, even at a 1500-fold lower dosage (0.01 mg/kg) than that of free MLN8237, rLDL-MLN still exhibits a much more effective therapeutic effect, with the PMF mice almost clear of blast cells. More importantly, rLDL-MLN promotes hematological recovery without any toxic side effects at the effective dosage, holding great promise in the targeted differentiation therapy of PMF patients.
Insights
A novel dual-targeting therapy, rLDL-MLN, shows promise for treating primary myelofibrosis (PMF). This agent effectively targets malignant cells and promotes differentiation with minimal side effects, offering a potential breakthrough for PMF patients.
Area of Science:
- Hematology
- Oncology
- Nanomedicine
Background:
- Primary myelofibrosis (PMF) is a serious myeloproliferative neoplasm characterized by abnormal megakaryoblasts and bone marrow fibrosis.
- Current treatments like MLN8237 target Aurora kinase A (AURKA) but cause significant side effects.
- There is a need for more effective and safer therapies for high-risk PMF.
Purpose of the Study:
- To develop and evaluate a novel dual-targeting therapy agent for PMF.
- To assess the efficacy and safety of rLDL-MLN in preclinical models of PMF.
- To investigate the mechanism of action of rLDL-MLN in targeting malignant hematopoietic stem/progenitor cells (HSPCs).
Main Methods:
- Development of a reconstituted low-density lipoprotein (rLDL) nanocarrier loaded with MLN8237 (rLDL-MLN).
- In vitro assessment of rLDL-MLN's effect on PMF cell lines and abnormal HSPCs, including proliferation, differentiation, and colony formation.
- In vivo evaluation of rLDL-MLN's therapeutic efficacy and safety in PMF mouse models.
Main Results:
- rLDL-MLN effectively inhibited proliferation and induced differentiation of PMF cell lines and abnormal HSPCs.
- The agent prevented the formation of erythrocyte and megakaryocyte colonies from abnormal HSPCs.
- rLDL-MLN demonstrated superior therapeutic effects at a significantly lower dosage compared to free MLN8237, clearing blast cells in PMF mice.
- Hematological recovery was promoted without toxic side effects at effective dosages.
Conclusions:
- rLDL-MLN represents a promising dual-targeting therapy for PMF, leveraging targeted delivery and AURKA inhibition.
- The nanocarrier effectively targets malignant HSPCs, enhancing therapeutic outcomes while minimizing toxicity.
- rLDL-MLN holds significant potential for clinical translation in the targeted differentiation therapy of PMF.
